December 10, 2013
CTI Clinical Trial and Consulting Services (CTI) announces David Facklam, MS has joined as Senior Director, Regulatory and Scientific Affairs.
Mr. Facklam has over 30 years of experience in clinical drug development in the pharmaceutical industry. Prior to joining CTI, Mr. Facklam held positions of increasing responsibility in the Global Development Operations group at Astellas Pharma, Inc., and most recently served as Global Head and Vice President of Global Clinical Science. As a senior leader, he provided oversight and strategic input across a broad array of clinical programs in transplantation, central nervous system, mycology, virology, urology, cardiology, hematology, and oncology. Mr. Facklam established the global clinical operations function at Astellas Pharma, Inc. and was responsible for establishing key outsourcing strategic alliances. Over his career, he led and developed many products and had direct involvement in the preparation of numerous briefing documents for the FDA, EMA and Health Canada, marketing applications, protocols, clinical study reports and abstracts and manuscripts. Mr. Facklam started his career in the pharmaceutical industry in the medical affairs group at the Upjohn Company, and he was also a founding member of the Chugai-Upjohn joint venture. Mr. Facklam earned a Masters Degree of Epidemiology at the University of Cincinnati.
“Dave has a deep scientific, analytical, and operational background, and he has direct experience leading complex global project teams to successful regulatory approvals,” according to Lynn Fallon, President of CTI. “His expertise in global regulatory and drug development will be a great asset to CTI.”